Adicet Bio has received Fast Track Designation from the FDA for its therapy candidate, ADI-270. This candidate is aimed at patients suffering from metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have already undergone specific treatments.
ADI-270 is an "off-the-shelf" gamma delta CAR T-cell therapy that targets CD70-positive cancers. It is engineered with a third-generation CAR design targeting CD70, using CD27 as the binding factor. It is further strengthened with a dominant negative form of the transforming growth factor-β receptor II (dnTGFβRII), making it a potentially effective treatment for patients with metastatic/advanced ccRCC and other patients with CD70+ tumors.
Adicet Bio is a biotechnology company that develops allogeneic gamma delta T-cell therapies for cancer and autoimmune diseases. The company’s approach involves engineering gamma delta T-cells with chimeric antigen receptors (CARs) to create off-the-shelf therapies to provide durable and effective treatments. Its leading product candidate, ADI-001, targets CD20 to treat relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma and autoimmune diseases. Another significant candidate is ADI-270 which targets renal cell carcinoma and other CD70+ solid tumors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.